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Abstract 
The sensory neuropeptide, calcitonin gene-related peptide (a-CGRP), has been implicated in the pathogenesis of migraine 
headache. The present study aimed to evaluate the effects of intracarotid infusions of human a-CGRP (10, 30 and 100 
pmol/kg • min; n = 8), as compared to that of saline (4 times; n = 8) on haemodynamics and blood flow distribution within the 
carotid circulation of the anaesthetized pig, using the radioactive microsphere method. Furthermore, the effects of antimigraine 
drugs, dihydroergotamine (100/xg/kg i.v; n = 4) or sumatriptan (300/zg/kg i.v.; n = 4), on these parameters were studied in the 
presence of the infusion of the highest concentration of human a-CGRP. Additionally, putative positive inotropic responses to 
human a-CGRP (10-9-10 -7 M) were investigated in porcine isolated atrial and ventricular trabeculae. Human a-CGRP 
increased carotid artery blood flow and conductance dose-dependently, together with an enhancement in vascular pulsations. 
These effects were associated with a fall in systemic blood pressure with concomitant increases in heart rate and cardiac output. 
The increase in carotid blood flow was reflected by an increase in total capillary blood flow, predominantly to extracerebral 
tissues including the dura, whereas blood flow through arteriovenous anastomoses remained stable. Both dihydroergotamine and 
sumatriptan reduced carotid blood flow and its capillary fraction without affecting systemic vascular conductance. In tissues, 
these drugs reversed blood flow increases due to human a-CGRP in most extracerebral tissues, but failed to reduce dural blood 
flow. In porcine isolated atrial and ventricular trabeculae, noradrenaline (10-8-10 5 M) increased force of contraction in a 
concentration-dependent manner. In contrast, human a-CGRP (10-9-10 -7 M) failed to increase force of contraction in atrial 
trabeculae (n = 6) and exerted only a moderate concentration-dependent positive inotropic effect in ventricular trabeculae 
(~ 25% of the response to 10 -5 M noradrenaline, n = 10). These data indicate that human a-CGRP caused arteriolar dilatation 
together with a fall in blood pressure in the pig. The tachycardia may be reflex-mediated, but the peptide also exerts a moderate 
positive inotropic action on ventricular trabeculae. The fall in systemic arterial blood pressure and the marked increase in 
capillary blood flow most likely prevented the opening of arteriovenous anastomoses. Furthermore, the antimigraine drugs, 
dihydroergotamine and sumatriptan, were able to reverse blood flow changes induced by human a-CGRP in the porcine carotid 
circulation. 
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1. Introduction 
In spite of  cons iderable debate  concerning the pre- 
cise mechanism, the pathogenes is  of migraine is associ- 
ated with d i latat ion of  large (extra)cranial  and arteri -  
ovenous anastomoses (Saxena, 1978; Drummond and 
Lance, 1988; Fer rar i  and Saxena, 1993). Recent  obser- 
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vations in animals and humans have suggested that 
both calcitonin gene-re lated pept ide (CGRP)  and nitric 
oxide (NO) may act in concert  in the vascular events 
observed during migraine attacks. The 37-amino acid 
pept ide,  CGRP,  is abundant ly  present  in sensory fi- 
bres, including f ibres innervating the heart  and tr igemi- 
nal vascular system (Mulderry  et al., 1985; Uddman et 
al., 1986; Suzuki et al., 1989). The pept ide  has been 
shown to be a potent  vasodi lator  exert ing di f ferent ial  
regional  haemodynamic  effects (Brain et al., 1985; 
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Franco-Cereceda et al., 1987; Gardiner et al., 1989). In 
migraineurs, elevated plasma levels of CGRP have 
been observed in the extracerebral circulation during 
headache (Goadsby et al., 1990) and antimigraine 
agents like dihydroergotamine and sumatriptan re- 
duced elevated CGRP plasma levels in these patients, 
as well as in cats during trigeminal nerve stimulation 
(Goadsby and Edvinsson, 1993). Likewise, nitrova- 
sodilators, which are generally thought o act by releas- 
ing NO (Ignarro, 1990), induce more pronounced 
headache (Olesen et al., 1993) and cranial artery di- 
latation in migraine patients than in normal subjects 
(Thomsen et al., 1993). Finally, nitrovasodilators in- 
crease blood flow through arteriovenous anastomoses 
in the carotid circulation of the pig (Van Gelderen et 
al., 1995) and may activate perivascular sensory nerves 
to release CGRP in cerebral as well as cutaneous 
microvessels (Wei et al., 1992; Holzer and Jo~ic, 1994). 
The present study aimed to evaluate the effects of 
human a-CGRP on haemodynamics and blood flow 
distribution within the carotid circulation of the pig, 
using the radioactive microsphere method. Since dihy- 
droergotamine and sumatriptan have been shown to 
reduce carotid blood flow in pigs (Den Boer et al., 
1992a,b), we also studied the effects of these two drugs 
on haemodynamics and carotid blood flow distribution 
during the infusion of human a-CGRP. 
Additionally, a-CGRP has been shown to increase 
cardiac output (Lappe et al., 1987; Wang et al., 1989; 
Gardiner et al., 1991) and positive inotropic responses 
have been described in isolated atria of various species 
(Saito et al., 1987; Sigrist et al., 1986; Franco-Cereceda 
et al., 1987; Duet  al., 1994). As preliminary experi- 
ments demonstrated an enhanced cardiac output fol- 
lowing human a-CGRP in pigs and as little is known 
about its putative inotropic effects in the pig heart, the 
effect of a-CGRP was investigated further in porcine 
isolated atrial and ventricular trabeculae. 
A preliminary account of some of the results was 
presented at the XIIth International Congress of Phar- 
macology (Van Gelderen and Saxena, 1994). 
2. Materials and methods 
The protocol of this study was submitted to and 
approved by the Institutional Committee for the use of 
animals. 
2.1. General (in vivo) 
After an overnight fast, 16 domestic pigs (Yorkshire 
× Landrace; 15-17 kg) were anaesthetized with i.m. 
injection of ketamine (25 mg/kg) and midazolam (0.3 
mg/kg). Following injection of thiopentone (6 mg/kg) 
in the middle ear vein, the animals were intubated and 
connected to a respirator (Bear 2E, BeMeds, Baar, 
Switzerland) for intermittent positive pressure ventila- 
tion. By adjusting oxygen supply, respiratory rate and 
tidal volume, arterial blood gas values were kept within 
the physiological range (pH 7.39-7.49; pCO 2 37-44; 
pO 2 100-130). Anaesthesia was maintained by a con- 
tinuous i.v. infusion with a mixture of fentanyl (18-38 
/zg/kg/h)  and thiopental (6-12 mg/kg/h) .  This 
anaesthetic regimen was used to preserve the vasocon- 
strictor tone in cranial arteriovenous anastomoses that 
is necessary to study mechanisms involved in opening 
arteriovenous anastomoses (Den Boer et al., 1993). 
Due to differences in the sensitivity of individual ani- 
mals, the infusion rate was adjusted in each animal 
using two criteria: (i) absence of blinking reflex, indica- 
tive of appropriate anaesthesia and (ii) venous oxygen 
saturation values below 60%, indicative of low arteri- 
ovenous anastomotic blood flow. 
A catheter was introduced into the aortic arch via 
the left femoral artery and was connected to a pressure 
transducer (Statham P23, Hato Rey, Puerto Rico) for 
the measurement of arterial blood pressure as well as 
withdrawal of blood samples to determine blood gases 
(ABL-510, Radiometer, Copenhagen, Denmark). Car- 
diac output, pulmonary arterial blood pressure and 
body temperature were measured with a 6F-Swan-Ganz 
thermodilution catheter (Corodyn, Braun Melsungen, 
Melsungen, Germany) introduced into the pulmonary 
artery via the left femoral vein and connected to a 
cardiac output computer (WTI, Rotterdam, Nether- 
lands) as well as to a pressure transducer. Mean arte- 
rial (MAP) and mean pulmonary artery (MPAP) pres- 
sures were calculated from the respective systolic (SBP) 
and diastolic (DBP) blood pressures as: MAP or 
MPAP = DBP + (SBP - DBP)/3.  Heart rate was 
recorded using a tachograph triggered from blood 
pressure signals as well as counted directly from these 
signals over a 30-s recording interval. Systemic vascular 
conductance was calculated by dividing cardiac output 
by mean arterial pressure. The right common carotid 
artery was dissected free and the total carotid blood 
flow was measured with a flow probe (internal diame- 
ter: 2.5 or 3 mm) connected to a sine-wave lectromag- 
netic flow meter (Transflow 600-system, Skalar, Delft, 
Netherlands). Carotid vascular conductance was calcu- 
lated by dividing carotid blood flow by mean arterial 
pressure and vascular pulse amplitude was calculated 
from the flow signals as the difference in systolic and 
diastolic blood flow values. Two hubless needles (exter- 
nal diameter 0.5 mm), bent at right angles and con- 
nected to polyethylene tubing (internal diameter 0.5 
mm), were inserted into the common carotid artery 
against he direction of the blood flow for administra- 
tion of radioactive microspheres or drugs. The right 
jugular vein was cannulated to collect venous blood 
samples to determine venous blood gases. All catheters 
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were filled with a heparin sodium solution (80 IU/ml)  
to prevent blood clotting. During the experiment, 
physiological saline was infused to compensate for fluid 
loss and body temperature was kept between 37 and 
38°C. 
2.2. D&tribution of  common carotid artery blood flow 
As described extensively by Johnston and Saxena 
(1978), the distribution of common carotid artery blood 
flow was measured using repeated injections of ra- 
dioactive microspheres (mean + S.D. diameter: 15 + 1 
/zm; NEN Company, Dreieich, Germany) with differ- 
ent labels (14lEe, ll3Sn, l°3Ru, 95Nb or 468c). Briefly, a 
suspension of approximately 250 000 microspheres was 
vortexed and injected into the common carotid artery 
at baseline and following the various treatments. Mi- 
crospheres were injected against the direction of the 
blood flow to ensure uniform mixing. At the end of the 
experiment, the animals were killed and the heart, 
kidneys, lungs and the different intra-and extracranial 
tissues were dissected out, weighed and put in vials. 
The radioactivity in these vials was counted for 10 min 
in a y-scintillation counter (Packard, Minaxi Auto- 
gamma 5000) using suitable windows for discriminating 
between the different isotopes. Radioactivity was 
counted in whole tissues, except in the case of bone, fat 
and skin, where aliquots (more than 50% of total 
weight) were analyzed. 
Tissue (capillary) blood flow was calculated by mul- 
tiplying the ratio of tissue and total radioactivity by 
total carotid blood flow at the time of injection, using a 
set of computer programs (Saxena et al., 1980). Since 
radioactivity was absent in the heart and kidneys, all 
radioactive microspheres reaching the venous side of 
the circulation had passed through arteriovenous anas- 
tomoses to be ultimately sieved in the lungs (see John- 
ston and Saxena, 1978; Saxena and Verdouw, 1982). 
Therefore, the amount of radioactivity in the lungs 
represents the arteriovenous anastomotic fraction of 
common carotid blood flow. 
2.3. Isolated atrial and ventricular trabeculae 
Cardiac tissues were obtained from pigs at the end 
of control (saline) experiments and atrial and ventricu- 
lar trabeculae were set up for recording of contractions 
as described previously (Schoemaker et al., 1992; Duet  
al., 1994). Briefly, after excision, pieces of atrial and 
ventricular myocardium were placed in ice-chilled oxy- 
genated Krebs buffer (composition in mM: NaC1 118, 
KCI 4.7, CaCI 2 2.5, MgSO 4 1.2, NaHCO 3 25, KHPO 4 
1.2 and glucose 8.3) and atrial and ventricular trabecu- 
lae (< 1 mm thickness) were carefully dissected free. 
The trabeculae were mounted in organ baths contain- 
ing Krebs buffer (gassed with 95% 0 2 and 5% CO2; 
37°C) and isometric tension was recorded with a Har- 
vard transducer. Resting tension was set to 750 and 
1950 mg for atrial and ventricular tissues, respectively, 
in order to provide optimal oading conditions. Tissues 
were paced at 1 Hz, using electrical field stimulation (3 
ms, voltage 20% above threshold). 
2.4. Experimental protocols 
In vivo experiments 
After a 45-min stabilization period, the animals were 
assigned at random to treatment (intracarotid infu- 
sions) with either saline (4 times, 125/xl/min, n = 8) or 
human a-CGRP (10, 30 and 100 pmol/kg • min, n = 8). 
Each dose was infused for 10 min to obtain stable 
blood flow signals. At baseline and after each infusion 
period, haemodynamic variables were collected and 
radioactive microspheres were injected. After the high- 
est dose of human a-CGRP (100 pmol /kg,  min), infu- 
sion was continued and either dihydroergotamine (100 
/zg/kg i.v.; n = 4) or sumatriptan (300 /xg/kg i.v.; 
n = 4) was injected and all variables were reassessed 
after 10 min. 
In vitro experiments 
Baseline force of contraction was measured after 
stabilization, and inotropic responsiveness was assessed 
by making a concentration-response curve for nor- 
adrenaline (10-8-10 -5 M). The maximum concentra- 
tion of noradrenaline was restricted to 10 -5 M, since 
tissues were irreversibly damaged after higher concen- 
trations (see Schoemaker et al., 1992; Duet  al., 1994). 
Tissues with a response to 10 -5 M noradrenaline 
smaller than 25 mg were excluded from further analy- 
sis. 
After the tissues had been washed 6 times and 
allowed to stabilize, a concentration-response curve for 
human a-CGRP (10-9-10 -7 M) was obtained in both 
atrial and ventricular tissues. Responses to human 
a-CGRP were expressed as percentages of the re- 
sponse to 10 -5 M noradrenaline. Following another 
wash and stabilization period of at least 10 min, a 
second noradrenaline concentration-response curve 
was made to check the viability of the tissues. 
2.5. Data presentation and analysis 
The effect of saline and human a-CGRP treatment 
in the two groups of anaesthetized pigs was analyzed 
by a repeated-measurement analysis of variance. When 
the samples represented different populations, the val- 
ues after each treatment were compared to baseline 
values by using Duncan's new multiple range test. 
Subsequently, the percent changes from baseline val- 
ues among groups were tested using Student's t-test. 
Baseline values for isolated atrial and ventricular tra- 
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beculae were compared using an unpaired t-test. The 
effects of noradrenaline and human a-CGRP were 
analyzed with an analysis of variance for repeated 
measurements. In all cases, statistical significance was 
accepted at a level of P < 0.05. 
2.6. Compounds 
The compounds used were: dihydroergotamine m - 
sylate (Wander-Pharma, Uden, Netherlands), fentanyl 
citrate (Janssen Pharmaceutica, Beerse, Belgium), hep- 
arin sodium (Heparin Leo, Leo Pharmaceutical Prod- 
ucts, Weesp, Netherlands), human a-CGRP (Saxon 
Biochemicals, Hannover, Germany), ketamine HC1 
(Apharmo, Arnhem, Netherlands), midazolam (Dor- 
micum, Roche, Mijdrecht, Netherlands), noradrenaline 
bitartrate (Sigma, St. Louis, MO, USA), sumatriptan 
(Glaxo Group Research, Ware, UK), thiopental sodium 
(Rh6ne-Poulenc Rorer, Amstelveen, Netherlands)• All 
chemicals were dissolved in sterile saline, except fen- 
tanyl citrate which was dissolved in propylene glycol 
and subsequently diluted in distilled water• 
3. Results 
3.1. Haemodynamics 
Systemic and carotid haemodynamic variables mea- 
sured at baseline and after intracarotid infusions with 
either saline or human a-CGRP and following injec- 
tions with either sumatriptan or dihydroergotamine  
the presence of human a-CGRP infusion (100 
pmol/kg • min) are depicted in Table 1. No differences 
were observed between the two groups at baseline, and 
infusion of saline caused no significant change in these 
variables. In contrast, human a-CGRP reduced mean 
arterial blood pressure with a maximum decrease of 
31 + 4% (100 pmol/kg, min). Heart rate, cardiac out- 
put and systemic vascular conductance increased ose 
dependently with a maximum of 78 + 13%, 44 + 14% 
and 104 + 8%, respectively, whereas no change was 
observed in stroke volume• Carotid blood flow and 
carotid vascular conductance were enhanced following 
human a-CGRP with a maximum increase of 199 _+ 
46% (30 pmol/kg • min) and 277 + 58% (100 pmol/kg 
• min), respectively (Fig. 1; Table 1). Together with the 
Table 1 
Systemic and carotid haemodynamic variables measured at baseline and after intracarotid infusions of either saline (control; n = 8) or human 
a-CGRP (n = 8) and following injections of either sumatriptan (SUM, 300 p,g/kg i.v.; n = 4) or dihydroergotamine (DHE, 100/zg/kg i.v.; n = 4) 
in the presence of human a-CGRP (100 pmol /kg  • min) 
Saline or human a-CGRP (pmol /kg  - min) 
Baseline 10 30 100 100 + SUM 100 + DHE 
MAP (ram Hg) 
Saline 86 _ 4 83 ± 4 85 + 4 85 + 4 84 ± 4 - 
a -CGRP 89 + 2 86 ± 2 76 + 3a  61 + 3a  49 + 5 t 52 + 4 
HR (beats/min) 
Saline 76 + 6 74 ± 5 74 ± 6 75 + 5 74 ± 6 - 
a -CGRP 80 ±10 90 ±11 104 ± 9a  139 +13a 114 ±24 134 ±18 
CO (l / min) 
Saline 1.3 ± 0.1 1.3 ± 0.1 1.3 + 0.1 1.3 ± 0.1 1.4 ± 0.2 - 
a -CGRP 1.4 ± 0.1 1.7 ± 0.2 1.9 ± 0.2 a 1.9± 0.2 a 1.5 ± 0.2 1.6 ± 0.2 
SV (ml) 
Saline 18 ± 0.8 18 ± 0.8 18 ± 0.7 18 ± 0.8 19 ± 1.0 - 
a -CGRP 18 ± 1.5 19 ± 1.7 18 ± 1.7 15 ± 2.4 15 ± 3.0 13 ± 3.0 
SVC (ml / min . mm Hg) 
Saline 16 ± 1 16 ± 1 16 ± 1 16 ± 1 16 ± 2 - 
a -CGRP 15 ± 1 19 ± 2 25 ± 2 a 31 ± 2 a 31 ± 1 31 ± 1 
CVC (ml / min • mm Hg) 
Saline 60 ± 8 66 ± 9 67 ±12 70 ±I0  64 ± 4 - 
ot-CGRP 58 ± 4 118 ±13 a 193 ±18 a 207 ±20 a 165 ±21b 145 ±23b 
CFP (ml / min) 
Saline 47 ±10 46 ±11 45 ± 9 45 ± 8 47 ± 9 - 
a -CGRP 67 ± 7 74 ± 6 108 + 9 a 159 ± 16 a 148 ± 7 181 ±34 
Values represent means _+ S.E.M.; a p _< 0.05 versus saline; b p _< 0.05 versus human a-CGRP (100 pmol /kg  • min). HR, heart rate; MAP, mean 
arterial blood pressure; CO, cardiac output; SV, stroke volume; SVC, systemic vascular conductance; CVC, carotid vascular conductance; CFP, 
carotid flow pulse. 
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enhanced carotid blood flow, a significant increase in 
vascular pulse amplitude was observed with human 
a-CGRP,  30 and 100 pmol /kg ,  min; maximum in- 
crease from baseline 142 + 19% (Table 1). 
Intravenous injections of either sumatriptan (300 
/zg/kg) or dihydroergotamine (100/~g/kg) in the pres- 
ence of intracarotid infusions of human a -CGRP (100 
pmol /kg ,  min) reduced mean arterial blood pressure 
by 42 + 5% and 33 + 5%, respectively, but induced no 
further change in the other systemic haemodynamic 
variables (Table 1). Both carotid blood flow and carotid 
vascular conductance were reduced by sumatriptan (42 
+ 3% and 23 + 6%, respectively) and dihydroergo- 
tamine (33 + 5% and 26 + 4%, respectively) (Fig. 1; 
Table 1). Carotid flow pulse remained stable following 
either drug (Table 1). 
3.2. Carotid blood f low distribution 
The human a-CGRP- induced increase in carotid 
blood flow was confined to the capillary fraction, which 
was increased from baseline (41 _+ 4 ml /min)  by 237 _+ 
45% (30 pmol /kg  • min). At baseline, 21 + 5% (n = 16) 
of the total carotid blood flow was directed towards 
arteriovenous anastomoses and no differences were 
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Fig. 1. Carotid blood flow and its distribution over arteriovenous 
anastomotic and capillary fractions at baseline (B) and after intrac- 
arotid infusions of saline (4 times, n = 8; left panels) or human 
a-CGRP (10, 30 and 100 pmol/kg,  min, n = 8; right panels), followed 
by either sumatriptan (SUM; 300 ,u.g/kg i.v.; n = 4) or dihydroergo- 
tamine (DHE; 100 /zg/kg i.v.; n = 4) in the presence of human 
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tissues at baseline (B) and after intracarotid infusions of saline (4 
times, n=8; left panels) or human a-CGRP (10, 30 and 100 
pmol/kg-min, n= 8; right panels), followed by either sumatriptan 
(SUM; 300 /zg/kg i.v.; n = 4) or dihydroergotamine (DHE; 100 
/zg/kg i.v.; n = 4) in the presence of human a-CGRP (100 pmol/kg- 
min). Values represent means + S.E.M.; * P < 0.05 versus aline val- 
ues; ÷ P < 0.05 versus human a-CGRP. 
observed between the two groups. Neither saline nor 
human a -CGRP induced changes in the arteriovenous 
anastomotic fraction (Fig. 1). Likewise, the increase in 
carotid vascular conductance was reflected by an in- 
crease in capillary conductance, which increased from 
baseline (46 _+ 4 ml /min .mm Hg) to a maximum of 
330 + 57% (data not shown)• Sumatriptan and dihy- 
droergotamine reduced equally the human a-CGRP-  
induced increase in capillary blood flow by 42 _+ 4% 
and 44 _+ 5%, respectively, whereas neither drug af- 
fected arteriovenous anastomotic blood flow (Fig. 1). 
Similarly, sumatriptan and dihydroergotamine reduced 
capillary conductance by 23 _+ 6% and 38 _+ 5%, re- 
spectively, without changing arteriovenous anastomotic 
conductance (data not shown). 
Human a -CGRP enhanced tissue blood flow dose 
dependently in extracerebral tissues by 308 + 49% (30 
pmol /kg  • min) without changing total brain blood flow. 
In cranial tissues, dural blood flow was increased ose 
dependently from baseline (4.0 _+ 0.8 ml /min .  100 g) 
to a maximum of 367 _+ 111% (Fig. 2). Tissue blood 
flow was significantly enhanced in all extracranial tis- 
sues, including the bones, ears, eyes, fat, muscles, sali- 
vary glands, skin and tongue (Fig. 3). Major increases 
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Fig. 3. Tissue blood flow to extracerebral tissues at baseline (B) and after intracarotid infusions of saline (4 times, n = 8; left panels) or human 
a-CGRP (10, 30 and 100 pmol/kg • min, n = 8; right panels), followed by either sumatriptan (SUM; 300/zg/kg i.v.; n = 4) or dihydroergotamine 
(DHE; 100 ~g/kg i.v.; n = 4) in the presence of human a-CGRP (100 pmol/kg • min). Values represent means + S.E.M.; * P < 0.05 versus 
saline values; ÷ P < 0.05 versus human c~-CGRP. 
were observed in the ears and skin, with a maximum 
increase of 802 + 198% and 808 + 160%, respectively 
(Fig. 3). +oo 
Sumatriptan and dihydroergotamine r versed hu- ] 
man a-CGRP-induced increases in extracerebral blood 
flow by 44 _+ 4% and 49 _+ 4%, respectively. In tissues, so j
dural blood flow was slightly reduced by both drugs 
(Fig. 2). The two drugs partially reversed the increases 
0 in blood flow in the ears, skin and muscles, without < 
affecting that to the bones and eyes (Fig. 3). Addition- z 
ally, dihydroergotamine reversed blood flow increases 
t,,- 
in the tongue, salivary glands and fat (Fig. 3). o 3o 
e~ 
¢/1 
a- 3.3. Myocardial contractility in vitro 
Baseline force of contraction was significantly lower 
in atrial tissue (50 + 16 mg, n = 6) than in ventricular 
tissue (595 + 137 mg, n = 10). As shown in Fig. 4, 
noradrenaline (10-8-10 -5 M) increased force of con- 
traction in a concentration-dependent manner in both 
tissues. With the highest concentration of noradrena- 
line (10 -5 M), the force of contraction increased by 
163_50 mg (n=6)  and 615_106 mg (n=10)  in 
atrial and ventricular trabeculae, respectively. At the 
Right atrium Left ventricle 
y/± 50 
-Log [NA] M -Log [NA] M 
30 
. -~+ + o 
. J "  
-Log [a-CGRP] M -Log [o-CGRP] M 
Fig. 4. Concentration-response curves for noradrenaline (NA; upper 
panels) (first: (3, second: v) and a-CGRP (o; lower panels) in 
porcine isolated right atrial (n = 6) and left ventricular (n = 10) 
trabeculae. Responses are expressed as percentages of the response 
to NA (10 5 M) at baseline. Values represent means_+S.E.M. 
E.M. Van Gelderen et al. / European Journal of Pharmacology 284 (1995) 51-60 57 
end of the protocol, noradrenaline (10 -5 M) induced 
positive inotropic responses comparable to the initial 
responses in ventricular trabeculae (100 _+ 6%, n = 10) 
whereas noradrenaline responses in atrial trabeculae 
were slightly reduced (84 + 7%, n = 6) (Fig. 4). 
In contrast to noradrenaline, human a-CGRP 
(10-9-10 -7 M) failed to increase force of contraction 
in the atrial tissue (baseline: 107_+ 26 mg, 10 -7 M 
human a-CGRP: 103 + 25 mg; n = 6 each), but ex- 
erted a moderate concentration-dependent positive in- 
otropic effect in ventricular tissue (Fig. 4). At 10 -7 M 
human o~-CGRP, ventricular contractile force in- 
creased from 545 + 110 mg at baseline up to 663 + 120 
mg, or 21 + 3% of the response to 10 -5 M noradrena- 
line (n = 10). 
4. Discussion 
4.1. Systemic haemodynamics 
The systemic haemodynamic effects of human a- 
CGRP have been described extensively in animals and 
humans (Franco-Cereceda et al., 1987; Lappe et al., 
1987; Gardiner et al., 1989, 1991; Wang et al., 1989). 
The fall in systemic blood pressure and increase in 
systemic vascular conductance observed with intrac- 
arotid infusions of the two highest concentrations (30 
and 100 pmol /kg-min)  of human a-CGRP are in 
accordance with these reports, but also show that the 
potent vasodilator action of the peptide was not limited 
to the carotid circulation. Since heart rate increased in 
parallel with the decline in blood pressure, it is reason- 
able to assume that changes in heart rate were barore- 
flex-mediated. Our unpublished observations in two 
pigs, anaesthetized with pentobarbital nd subjected to 
bilateral vagosympathectomy, support his view; intrac- 
arotid infusions of human a-CGRP (up to 100 
pmol /kg-min)  in these animals with markedly inhib- 
ited sympathetic tone (see Den Boer et al., 1993) did 
not increase heart rate, despite a pronounced fall in 
arterial pressure. It, however, remains possible that in 
other circumstances (e.g. the use of porcine a-CGRP 
in pigs) or in other species additional mechanisms, 
such as a direct chronotropic action or release of 
catecholamines, may contribute to the observed tachy- 
cardia. Indeed, heart rate responses to a-CGRP were 
attenuated but not completely abolished in dogs after 
cardiac denervation (Wang et al., 1989). A direct 
chronotropic effect of rat a-CGRP has also been ob- 
served in rat isolated atria (Sigrist et al., 1986), but no 
tachycardia was detected in conscious rats given human 
a-CGRP (Gardiner et al., 1989). On the other hand, 
catecholamine r lease was reported in dogs and man 
(Franco-Cereceda et al., 1987; Wang et al., 1989), and 
/3-adrenoceptor blockade abolished tachycardia in car- 
diac denervated ogs (Wang et al., 1989). 
As previously reported for rats (Lappe et al., 1987), 
cardiac output increased without changes in stroke 
volume, most likely, reflecting a reduction in afterload, 
as indicated by the fall in systemic blood pressure. 
However, when systemically infused in a comparable 
dose, human a-CGRP enhanced indices of contractil- 
ity in conscious rats, despite a marked reduction in 
stroke index, possibly due to the reduction in venous 
pressure (Gardiner et al., 1991). If this was also the 
case in our experiments, the putative positive inotropic 
action of human a-CGRP (see Section 4.3) was masked 
in pigs by concomitant venodilatation. 
Both dihydroergotamine and sumatriptan failed to 
reverse human a-CGRP-induced systemic haemody- 
namic changes. Either drug tended to reduce mean 
arterial blood pressure, significantly so only in the case 
of sumatriptan. Since the latter was shown previously 
to reduce cardiac output in anaesthetized pigs (Den 
Boer et al., 1992b), the small change in this variable 
may have accounted for the additional reduction in 
blood pressure. As no significant changes in systemic 
vascular conductance were observed with either dihy- 
droergotamine or sumatriptan, both drugs exerted a 
selective vasoconstrictor effect in the carotid vascula- 
ture. 
4.2. Carotid haemodynamics 
Carotid vascular pulsations 
The increase in carotid vascular pulsations caused 
by human c~-CGRP is partially in accord with previous 
observations using Doppler flow measurements in hu- 
mans, when the peptide enhanced pulsatility in the 
internal carotid artery, but not in the common carotid 
artery (MacDonald et al., 1989). As argued before, 
these increased pulsations most likely reflect changes 
in vascular compliance following vasodilatation, though 
the precise mechanism is unclear (Van Gelderen et al., 
1995). It is to be noted that local pulsatile flow may be 
influenced by changes in systemic vascular resistance 
and, furthermore, similar changes in pulsatility are also 
observed with histamine and nitrovasodilators, preclud- 
ing the existence of a specific mechanism (Graham and 
Wolff, 1938; Thomsen et al., 1993; Van Gelderen et al., 
1995). The inability of either dihydroergotamine or
sumatriptan to change the carotid vascular pulsations 
induced by human a-CGRP may argue against vaso- 
dilatation as the sole underlying mechanism. Addition- 
ally, it is possible that the dose of the antimigraine 
drugs was not sufficient o oppose the enhanced vascu- 
lar pulsations during continued infusion of a high dose 
of human a-CGRP. 
Carotid blood flow distribution 
In keeping with the observations in rats (Gardiner et 
al., 1989, 1991), human a-CGRP elevated common 
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carotid blood flow dose dependently, associated with 
pronounced increases in regional tissue blood flow, 
indicating arteriolar dilatation. In the presence of a 
high concentration of human a-CGRP, sumatriptan 
and dihydroergotamine reduced carotid blood flow to 
an extent similar to that reported in the absence of the 
peptide (Den Boer et al., 1992a), suggesting that their 
vasoconstrictor action in this vessel does not depend on 
the level of circulating human a-CGRP. 
As previously reported (Den Boer et al., 1993; Van 
Gelderen et al., 1995), approximately 21% of the 
carotid blood flow (compared to over 70% in anaes- 
thetized pigs, Den Boer et al., 1992a) was shunted 
through arteriovenous anastomoses, indicating that, at 
baseline, these vessels were largely under sympathetic 
constrictor tone. Despite its potent vasodilator action, 
human a-CGRP failed to affect blood flow through 
arteriovenous anastomoses. These vessels appear to be 
innervated by sensory nerves (Gorgas et al., 1977; Hales 
and Molyneux, 1988) and CGRP-containing fibres have 
been demonstrated immunohistochemically in the 
proximity of arteriovenous anastomoses in the dog 
tongue (Hino et al., 1993). Moreover, in a similar dose, 
CGRP increased arteriovenous anastomoses blood flow 
in the sheep hind limb (Mogg et al., 1992). The lack of 
effect of human a-CGRP in our study is not explained 
by the difference in peptide used (human a-CGRP 
versus rat CGRP), since more pronounced vasodilator 
effects have been reported with human a-CGRP than 
with rat a-CGRP (Gardiner et al., 1989). As an ele- 
vated shunt flow was observed in the sheep hind limb, 
apparently without significant changes in systemic blood 
pressure and capillary flow (Mogg et al., 1992), it is 
possible that the pronounced increase in capillary blood 
flow in conjunction with the marked rise in systemic 
vascular conductance prevented the opening of arteri- 
ovenous anastomoses in the carotid circulation of the 
pig by way of a 'steal-like' phenomenon. As nitrova- 
sodilators have been reported to enhance blood flow 
through arteriovenous anastomoses under comparable 
conditions (Van Gelderen et al., 1995), it seems un- 
likely that, in this part of the circulation, nitrovasodila- 
tors act via the release of CGRP (Wei et al., 1992; 
Holzer and Jo6ic, 1994). 
The antimigraine drugs, dihydroergotamine and 
sumatriptan, have been shown to reduce blood flow 
through arteriovenous anastomoses in pigs with a high 
shunt flow (Den Boer et al., 1992a). Since arteriove- 
nous anastomoses were largely closed and repeated 
infusions with human a-CGRP failed to increase arte- 
riovenous anastomotic blood flow, such a constrictor 
action could not be detected in the present experi- 
ments. 
In the porcine carotid circulation, human a-CGRP 
increased extracerebral b ood flow without affecting 
intracerebral flow. The predominant action on extrac- 
erebral tissues, most markedly reflected by the major 
changes in cutaneous tissues (skin and ears) supports 
the contention that extracranial vascular dilatation and 
pulsation indeed have a role in migraine headache 
(Graham and Wolff, 1938; Drummond and Lance, 
1988). However, the absence of cerebral blood flow 
changes eems to be in conflict with the enhanced 
cerebral blood flow together with elevated CGRP lev- 
els in the external jugular vein following stimulation of 
the trigeminal ganglion (Goadsby and Edvinsson, 1993) 
as well as with the increased vessel diameter in the 
feline cerebral microcirculation observed with CGRP 
(Wei et al., 1992). This discrepancy is most likely 
attributable to methodological differences since, in the 
former study, cerebral blood flow was measured by 
laser Doppler flowmetry, detecting changes in large 
intracerebral vessels (not detected by microspheres), 
whereas in the latter study CGRP was applied topi- 
cally, producing relatively high local concentrations. 
Finally, it may be argued that a putative vasodilator 
action of human a-CGRP in porcine cerebral capillar- 
ies is effectively opposed by cerebral autoregulation. 
Within the porcine cranial circulation, dural blood 
flow was significantly enhanced by human a-CGRP. 
The dura mater, which is innervated by CGRP-contain- 
ing nerves (Uddman et al., 1986; Suzuki et al., 1989), is 
regarded a likely source of headache, and plasma levels 
of CGRP appear to be elevated in the cranial venous 
effluent in migraineurs (Friberg et al., 1994). Thus, it is 
plausible that enhanced ural blood flow, together with 
increased vascular pulsatility, contributes to migraine 
headache. However, in spite of an increase in carotid 
vascular esistance indicating vasoconstriction, antimi- 
graine drugs like dihydroergotamine and sumatriptan 
failed to reduce dural blood flow in pigs (Den Boer et 
al., 1992a), whereas sumatriptan reduced feline pial 
diameter only after topical application (Connor et al., 
1992). Moreover, in the present study with presumably 
high levels of CGRP, both sumatriptan and dihydroer- 
gotamine only slightly reduced dural blood flow and 
failed to reduce carotid vascular pulsations. 
4.3. Myocardial contractility in vitro 
In contrast to noradrenaline, human a-CGRP failed 
to increase force of contraction i  porcine atrial tissue 
but increased contractility in ventricular tissue. So far, 
a positive inotropic action in the atrium rather than 
ventricles has been observed in the rat (Sigrist et al., 
1986; Ishikawa et al., 1987), guinea pig (Saito et al., 
1987) and human myocardium (Sigrist et al., 1986; Du 
et al., 1994), suggesting a rather uniform mode of 
action, at least on atrial trabeculae. However, the dis- 
crepancy may be attributable to species differences. 
For example, few CGRP-specific binding sites have 
been detected in guinea pig ventricles (Ishikawa et al., 
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1988), whereas these sites could be demonstrated in 
porcine ventricular tissue (Miyauchi et al., 1988). At 
present, no data are available about specific binding 
sites for CGRP in the porcine atrium. The ability of 
human a-CGRP to increase the force of contraction i
ventricular t abeculae is in accord with the detection of 
binding sites for this peptide as well as with the obser- 
vation of positive inotropic responses in ventricular 
false tendons (Miyauchi et al., 1988). Moreover, the 
magnitude of the inotropic response at 10 -7 M human 
CGRP, being approximately 25% of the isoprenaline 
control curve, was comparable with that in our study. 
Although these moderate ventricular inotropic re- 
sponses upport he hypothesis of a positive inotropic 
effect in anaesthetized pigs, it remains to be estab- 
lished whether such concentrations actually occur in 
vivo. 
In summary and conclusion, intracarotid infusion of 
human a-CGRP caused arteriolar dilatation in the pig, 
which was accompanied by hypotension, tachycardia 
and an increase in cardiac output. Within the carotid 
circulation, vasodilatation was largely confined to ex- 
tracerebral tissues and the marked increase in capillary 
blood flow together with the fall in systemic blood 
pressure most likely prevented the opening of arteri- 
ovenous anastomoses. Furthermore, in the presence of 
high levels of human a-CGRP, the antimigraine drugs, 
dihydroergotamine and sumatriptan, reversed blood 
flow changes induced by human a-CGRP in extracere- 
bral tissues. 
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